BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31187861)

  • 1. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
    Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
    Ibrahim U; Saqib A; Atallah JP
    Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.
    Zeng L; Zhang Y; Yang N
    J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651
    [No Abstract]   [Full Text] [Related]  

  • 4. Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma.
    Jelli B; Taton O; D'Haene N; Remmelink M; Mekinda Z
    Eur J Case Rep Intern Med; 2021; 8(8):002749. PubMed ID: 34527619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.
    An N; Wang H; Zhu H; Yan W; Jing W; Kong L; Zhang Y; Yu J
    Onco Targets Ther; 2019; 12():7399-7404. PubMed ID: 31686847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
    Čoupková H; Vyzula R
    Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
    Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
    Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
    [No Abstract]   [Full Text] [Related]  

  • 8. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
    Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
    Watanabe M; Oizumi S; Kiuchi S; Yamada N; Yokouchi H; Fukumoto S; Harada M
    Intern Med; 2018 Apr; 57(7):993-996. PubMed ID: 29225262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
    van Veggel B; de Langen AJ; Hashemi SMS; Monkhorst K; Heideman DAM; Thunnissen E; Smit EF
    J Thorac Oncol; 2018 Aug; 13(8):1222-1226. PubMed ID: 29702285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.
    Ikeuchi T; Tokuyasu H; Ishikawa S
    Intern Med; 2019; 58(1):101-104. PubMed ID: 30606938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
    Kobayashi Y; Togashi Y; Yatabe Y; Mizuuchi H; Jangchul P; Kondo C; Shimoji M; Sato K; Suda K; Tomizawa K; Takemoto T; Hida T; Nishio K; Mitsudomi T
    Clin Cancer Res; 2015 Dec; 21(23):5305-13. PubMed ID: 26206867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.
    Liang SK; Ko JC; Yang JC; Shih JY
    Lung Cancer; 2019 Jul; 133():103-109. PubMed ID: 31200815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab.
    Tamiya M; Kunimasa K; Nishino K; Matsumoto S; Kawachi H; Kuno K; Inoue T; Kuhara H; Imamura F; Goto K; Kumagai T
    Invest New Drugs; 2021 Feb; 39(1):232-236. PubMed ID: 32556898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication.
    Wang XF; Zhao QT; Chen C
    Am J Ther; 2020; 27(5):e535-e537. PubMed ID: 31567148
    [No Abstract]   [Full Text] [Related]  

  • 16. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.
    Ackerman A; Goldstein MA; Kobayashi S; Costa DB
    J Thorac Oncol; 2012 Oct; 7(10):e19-20. PubMed ID: 22982663
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
    Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K
    Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
    Kauffmann-Guerrero D; Kahnert K; Kumbrink J; Syunyaeva Z; Tufman A; Huber RM
    Clin Lung Cancer; 2019 Jan; 20(1):59-62. PubMed ID: 30341016
    [No Abstract]   [Full Text] [Related]  

  • 19. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.
    Shi Y; Wang M
    Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.
    Li J; Zhu L; Stebbing J; Peng L
    J Cancer Res Ther; 2022 Sep; 18(5):1436-1439. PubMed ID: 36204894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.